Cancer Biomarkers Market 2020 - 2027 Global Size, Share, Industry Key Players like Abbott Laboratories, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Exact Sciences

According to the report, the global cancer biomarkers industry was estimated at $10.94 billion in 2019, and is expected to hit $26.97 billion by 2027, registering a CAGR of 11.8% from 2020 to 2027.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1443

Surge in number of patients suffering from various types of cancers such as prostate, breast, and lung cancer, rise in number of clinical trials, and high accuracy & reliability drive the growth of the global cancer biomarkers market. However, high cost associated with drug development and fatal effects of cancer drug therapy restrain the market growth. Furthermore, technological advancements in cancer therapy and focus on advanced treatment protocols are expected to create new growth opportunities for the market players.

Covid-19 scenario:

Several major market players have halted the manufacturing of cancer biomarker diagnostic tools amidst the lockdown enforeced by governments during the Covid-19 pandemic.
The demand for cancer biomarkers is expected to surge during the Covid-19 pandemic to diagnose conditions by identifying early stage cancers (diagnostic) and forecast how aggressive a condition can proceed in order to decide the course of treatment (prognostic). The medical diagnostics industry has not suffered the severe impacts.

Request for Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/1443?reqfor=covid

The genetic biomarkers segment to dominate during the estimated period-

Based on biomolecule, the genetic biomarkers segment contributed to nearly half of the global cancer biomarkers market revenue in 2019, and is anticipated to lead the trail till 2027. This is due to its accuracy and precision while detecting cancer and monitoring the effectiveness of the treatment. Simultaneously, the glycol-biomarkers segment would portray the fastest CAGR of 12.5% by 2027. Increase in awareness about the roles of glycosylation and other post translational modifications in cancer biology fuels the segment growth.

The omic technologies segment to maintain the lion's share by 2027-

Based on profiling technologies, the omic technologies segment accounted for more than half of the global cancer biomarkers market share in 2019, and is expected to rule the roost by the end of 2027. This is attributed to factors such as rise in use of personalized medicines for cancer treatment and growth in healthcare expenditure among people. The immunoassays segment, on the other hand, would register the fastest CAGR of 16.4% throughout the forecast period, owing to various advantages offered by immunoassays such as simultaneous analysis of multiple compounds, analysis at minute concentrations, and increased efficiency of diagnosis and treatment.

North America to dominate in terms of revenue-

Based on geography, North America held the major share, garnering more than one-third of the global cancer biomarkers market, owing to strong focus on innovation and technological advancements in healthcare & diagnostics in the region. At the same time, Asia-Pacific is expected to manifest the fastest CAGR of 15.1% from 2020 to 2027. This is due to increase in prevalence of cancer, rise in patient awareness, and increase in disposable incomes in the province.

Frontrunners in the industry-

Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
Bristol-Myers Squibb Company
Exact Sciences Corporation
F.Hoffmann-La Roche Ltd.
Abbott Laboratories
Qiagen N.V.
Merck KGaA
PerkinElmer, Inc.
Siemens AG

Access Full Report: https://www.alliedmarketresearch.com/cancer-biomarkers-market

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.